<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03833323</url>
  </required_header>
  <id_info>
    <org_study_id>ISR PAS</org_study_id>
    <nct_id>NCT03833323</nct_id>
  </id_info>
  <brief_title>Implantable System for Remodulin Post-Approval Study</brief_title>
  <acronym>ISR PAS</acronym>
  <official_title>Implantable System for Remodulin Post-Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Implantable System for Remodulin (ISR) Post Approval Study (PAS) is to
      provide evaluation and periodic reporting of the safety and effectiveness of Medtronic
      market-released ISR, including the catheter and the pump.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ISR PAS is an observational, prospective, non-randomized, multi-center study. It will
      enroll a minimum of 50 newly implanted patients at up to 10 US sites, observing and reporting
      catheter-related complications and pump failures through 5 years post implant.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Catheter-related complications</measure>
    <time_frame>Implant to 5 years post-implant</time_frame>
    <description>Number of adverse events requiring invasive intervention that are related to the ISR catheter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pump failures</measure>
    <time_frame>Implant to 5 years post-implant</time_frame>
    <description>Number of adverse events requiring invasive intervention that are related to the ISR pump.</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Implantable System for Remodulin (treprostinil)</intervention_name>
    <description>All patients will be implanted with the Implantable System for Remodulin (treprostinil).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Newly implanted patients that are intended to receive an ISR.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject or legally authorized representative provides written authorization and/or
             consent per institution and geographical requirements.

          -  Subject is intended to receive an eligible ISR product.

          -  Subject is at least 22 years of age.

        Exclusion Criteria:

          -  Subject is pregnant.

          -  Subject who is expected to be inaccessible for follow-up.

          -  Subject with exclusion criteria required by local law.

          -  Subject is currently enrolled in or plans to enroll in any concurrent drug and/or
             device study that may confound results (i.e. no required intervention that could
             affect interpretation of all-around product safety and or effectiveness).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bourge, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy A Lautenbach</last_name>
    <phone>763-514-2729</phone>
    <email>amy.a.lautenbach@medtronic.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2019</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAH</keyword>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Remodulin</keyword>
  <keyword>treprostinil</keyword>
  <keyword>DelIVery for PAH</keyword>
  <keyword>Implantable Pump</keyword>
  <keyword>Drug Pump</keyword>
  <keyword>Intrathecal Catheter</keyword>
  <keyword>Targeted Drug Delivery</keyword>
  <keyword>Programmable Pump</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

